Advocate, Memorial Hermann, Corewell, and Atlantic Health System are together contributing $8 million in “strategic” investments with the San Francisco company. 

When paired with willing older adults, talking AI can administer and assess preliminary dementia tests in much the same way—and with similar effectiveness—as human specialists.

Report errors can result in incorrect or delayed diagnoses and significantly impact disease management. 

Clinical validation testing proved CleaRecon DL’s 3D image reconstructions to be effective at reducing unwanted artifacts, offering clearer images in 98% of cases.

Researchers have used a state-of-the-art microscope and advanced AI to track clotting risks in CAD patients. The goal is to spot blood clots before they even happen, ensuring patients are prescribed the right therapy for their specific needs. 

Why do investors equate these companies with beautiful, mythical beasts? Because startups with such dazzling attributes are—or long were—rarely seen.

Where a cautious President Biden wanted to confine American AI know-how to America, a freewheeling President Trump wants to turn it loose—at least to select friends and allies.

Leaders with the publicly traded, Los Angeles-based organization discussed the possibility during RadNet’s first quarter earnings call on Monday.